Domača stran4507 • TYO
add
Shionogi & Co Ltd
Delnica
Vodilno podjetje na področju varovanja okoljaVrednostni papir, ki kotira v JPSedež podjetja: JP
Vodilno podjetje na področju varovanja okoljaVrednostni papir, ki kotira v JPSedež podjetja: JPPrejšnji trg. dan.
2144,00 ¥
Dnevni razpon
2110,00 ¥ - 2152,00 ¥
Letni razpon
1944,66 ¥ - 2712,33 ¥
Tržna kapitalizacija
1,87 bil. JPY
Povprečni obseg
2,60 mio.
Razm. P/E
11,76
Dividendna donosnost
2,67 %
Primarna borza
TYO
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (JPY) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 116,38 mrd. | −4,00 % |
Stroški poslovanja | 52,93 mrd. | −3,66 % |
Čisti dohodek | 52,50 mrd. | 9,30 % |
Čista dobičkovnost prihodkov | 45,11 | 13,86 % |
Earnings per share | — | — |
EBITDA | 53,13 mrd. | −5,14 % |
Efektivna davčna stopnja | 8,28 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (JPY) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 303,40 mrd. | 20,22 % |
Skupna sredstva | 1,46 bil. | 3,34 % |
Skupne obveznosti | 145,93 mrd. | −18,09 % |
Celoten lastniški kapital | 1,31 bil. | — |
Shares outstanding | 850,69 mio. | — |
Razmerje P/B | 1,28 | — |
Donosnost sredstev | 8,22 % | — |
Donosnost kapitala | 9,10 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (JPY) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 52,50 mrd. | 9,30 % |
Denar iz dejavnosti | 45,30 mrd. | 220,14 % |
Denar iz naložb | −17,63 mrd. | 47,30 % |
Denar iz financiranja | −1,11 mrd. | 94,50 % |
Neto sprememba denarnih sredstev | 21,45 mrd. | 158,43 % |
Prost denarni tok | 8,02 mrd. | 135,46 % |
Vizitka
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Generalni direktor
Datum ustanovitve
1878
Sedež organizacije
Spletno mesto
Zaposleni
4.959
